Krsnaa Diagnostics has announced that its Board of Directors has approved the issuance of unlisted, secured, redeemable, and transferable non-convertible debentures (NCDs) worth up to ₹430 crore. The approval was granted during the board meeting held on December 12, 2025, which ran from 11:30 AM to 12:40 PM IST.
The company stated that the issuance will be carried out through a private placement, aimed at strengthening its financial structure and supporting future growth initiatives.
Under the approved structure, Krsnaa Diagnostics will issue 43,000 NCDs with a face value of ₹1,00,000 each, aggregating to ₹430 crore. These debentures will remain unlisted and will have a tenure of seven years from the deemed date of allotment.
The NCDs will carry a fixed coupon rate, with both interest and principal repayment scheduled on a half-yearly basis. Redemption will take place in 13 equal instalments, beginning six months after the allotment date.
The company also confirmed that a charge will be created over identified assets as part of the security structure in accordance with the definitive agreements. No delays, defaults, cancellations, or changes to the proposed issuance were reported.
